(A) Body-weight gain of Gtf2ird1 Tg mice and the littermate controls (control) under HFD at 22°C. n=15. * P<0.05.
(B) GTT in Gtf2ird1 Tg mice and controls after 10 weeks of HFD at 22°C. n=6–7.
(C) ITT in Gtf2ird1 Tg mice and controls after 10 weeks of HFD at 22°C. n=6–7.
(D) Serum concentrations of fasting insulin in Gtf2ird1 Tg mice and controls after 11 weeks of HFD. n=6–8.
(E) Relative mRNA expression of pro-fibrosis genes in the inguinal WAT of Gtf2ird1 Tg mice and controls after 11 weeks of HFD. n=6. * P<0.05, ** P<0.01.
(F) Relative mRNA expression of pro-inflammatory genes in the inguinal WAT of Gtf2ird1 Tg mice and controls after 11 weeks of HFD. n=6.
(G) Body-weight gain of Gtf2ird1 Tg mice and controls under HFD under thermoneutrality (30°C). n=9–15.
(H) GTT in Gtf2ird1 Tg mice and controls after 10 weeks of HFD under thermoneutrality. n=6–7.
(I) Hydroxyproline content in the BAT (left) and the inguinal WAT (right) from Gtf2ird1 Tg mice and controls after 12 weeks of HFD under thermoneutrality. n=6–7. All the data are presented as means ± SEM.